Текст книги "COVID-19/SARS-CoV-2"

811. VanBlargan LA, Errico JM, Halfmann PJ, et al. An Infectious SARS-CoV-2 B.1.1.529 Omicron Virus Escapes Neutralization by Several Therapeutic Monoclonal Antibodies. Microbiology; 2021. doi:10.1101/2021.12.15.472828.

812. Cameroni E, Saliba C, Bowen JE. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Published December 14, 2021. Accessed December 23, 2021. https://www.biorxiv.org/content/10.1101/2021.12.12.472269v1.

813. WHO. Therapeutics and COVID-19: Living Guideline, 16 September 2022. WHO Accessed September 21, 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.5.

814. SARS-CoV-2 variants of concern and variants under investigation – https://bit.ly/3xhyF2d.

815. Redd AD, Nardin A, Kared H, et al. Minimal Cross-over between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8+ T Cell Epitopes Identified in COVID-19 Convalescent Individuals. Immunology; 2021. doi:10.1101/2021.12.06.471446.

816. Buchan SA, Tibebu S, Daneman N, et al. Increased household secondary attacks rates with Variant of Concern SARS-CoV-2 index cases. Clinical Infectious Diseases. 2021; (ciab496). doi:10.1093/cid/ciab496.

817. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein. Nature. Published online 2021. https://doi.org/10.1038/s41586-021-03402-9.

818. Sinha S, Tam B, Wang SM. Altered interaction between RBD and ACE2 receptor contributes towards the increased transmissibility of SARS CoV-2 delta, kappa, beta, and gamma strains with RBD double mutations. bioRxiv. Published online January 1, 2021:2021.08.30.458303. doi:10.1101/2021.08.30.458303.

819. Curran J, Dol J, Boulos L, et al. Transmission characteristics of SARS-CoV-2 variants of concern Rapid Scoping Review. medRxiv. Published online January 1, 2021:2021.04.23.21255515. doi:10.1101/2021.04.23.21255515.

820. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance. 2021;26 (24):2100509. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.24.2100509.

821. Dhar MS, Marwal R, Vs R, et al. Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science. Published online October 14, 2021:eabj9932. doi:10.1126/science. abj9932.

822. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 32. 17 December 2021. https://bit.ly/3lrmvBz.

823. Assessment of the further emergence and potential impact of the SARS-CoV-2 Omicron variant of concern in the context of ongoing transmission of the Delta variant of concern in the EU/EEA, 18th update,. Published online December 15, 2021. https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-assessment-further-emergence-omicron-18th-risk-assessment-december-2021.pdf.

824. Bager P, Wohlfahrt J, Fonager J, Albertsen. Increased Risk of Hospitalisation Associated with Infection with SARS-CoV-2 Lineage B.1.1.7 in Denmark. Available at SSRN: https://ssrn.com/abstract=3792894 or http://dx.doi.org/10.2139/ssrn.3792894.

825. Paredes MI, Lunn SM, Famulare M, et al. Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study. medRxiv. Published online January 1, 2021:2021.09.29.21264272. doi:10.1101/2021.09.29.21264272.

826. NERVTAG paper on COVID-19 variant of concern B.1.1.7. GOVUK. Published online 2021. https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of-concern-b117, http://files/64/nervtag-paper-on-covid-19-variant-of-concern-b117.html % [2021/02/08/18:37:19.

827. Pascall DJ, Mollett G, Blacow R, Bulteel N, et al. The SARS-CoV-2 Alpha variant causes increased clinical severity of disease. https://www.medrxiv.org/content/10.1101/2021.08.17.21260128v1.

828. Pearson CA, Eggo. Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2. https://bit.ly/3ZHP0JB.

829. Freitas ARR, Beckedorff OA, Cavalcanti LP de G, et al. The emergence of novel SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and sex profile of COVID-19 mortality: A population based ecological study. The Lancet Regional Health – Americas. 2021;1:100021. doi:10.1016/j.lana.2021.100021.

830. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada. medRxiv. Published online July 12, 2021:2021.07.05.21260050. doi:10.1101/2021.07.05.21260050.

831. McAlister FA, Nabipoor M, Chu A, Lee DS, Saxinger L, Bakal JA. Lessons from the COVID-19 Third Wave in Canada: The Impact of Variants of Concern and Shifting Demographics. Infectious Diseases (exc ept HIV/AIDS); 2021. doi:10.1101/2021.08.27.21261857.

832. Madhi SA, Kwatra G, Myers JE, et al. South African Population Immunity and Severe Covid-19 with Omicron Variant. Infectious Diseases (except HIV/AIDS); 2021. doi:10.1101/2021.12.20.21268096.

833. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Comparison of Outcomes from COVID Infection in Pediatric and Adult Patients before and after the Emergence of Omicron. Infectious Diseases (except HIV/AIDS); 2022. doi:10.1101/2021.12.30.21268495.

834. Muik A, Wallisch AK, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine—elicited human sera. Science. Published online 2021:eabg6105. https://bit.ly/3YhxqvW.

835. Gallais F, Gantner P, Bruel T, et al. Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection. medRxiv. Published online January 1, 2021:2021.05.07.21256823. doi:10.1101/2021.05.07.21256823.

836. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. Published online March 2021. https://www.ncbi.nlm.nih.gov/pubmed/33654292.

837. Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The Lancet. 2021;397 (10273):452—455. https://linkinghub.elsevier.com/retrieve/pii/S0140673621001835.

838. Public Health England (PHE). SARS-CoV-2 Variants of Concern and Variants under Investigation in England. Technical Briefing 20. Public Health England; 2021. https://bit.ly/3HQMUjG.

839. Planas D, Veyer D, Baidaliuk A, et al. Reduced Sensitivity of Infectious SARS-CoV-2 Variant B.1.617.2 to Monoclonal Antibodies and Sera from Convalescent and Vaccinated Individuals. Microbiology; 2021. doi:10.1101/2021.05.26.445838.

840. Public Health England (PHE). SARS-CoV-2 Variants of Concern and Variants under Investigation..Technical Briefing 18.; 2021. https://bit.ly/3DXps37.

841. Altarawneh H, Chemaitelly H, Tang P, et al. Protection Afforded by Prior Infection against SARS-CoV-2 Reinfection with the Omicron Variant. Epidemiology; 2022. doi:10.1101/2022.01.05.22268782.

842. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Accessed November 30, 2021. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.

843. Public Health England. SARS-CoV-2 lateral flow antigen tests: evaluation of VOC1 (Kent, UK) and VOC2 (South Africa). GOV.UK. Accessed June 21, 2021. https://www.gov.uk/government/publications/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-voc1-and-voc2/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-voc1-kent-uk-and-voc2-south-africa.

844. Bekliz M, Adea K, Essaidi-Laziosi M, et al. Analytical Performance of Eleven SARS-CoV-2 Antigen-Detecting Rapid Tests for Delta Variant. Infectious Diseases (except HIV/AIDS); 2021. doi:10.1101/2021.10.06.21264535.

845. Molenkamp R, Igloi Z. Evaluation of Antigen rapid test and PCR test to Omicron variant.

846. Ministero della Salute INDICAZIONI AD INTERIM PER L’EFFETTUAZIONE DELL’ISOLAMENTO E DELLA ASSISTENZA SANITARIA DOMICILIARE NELL’ATTUALE CONTESTO COVID-19 https://www.epicentro.iss.it/coronavirus/pdf/rapporto-covid-19-1-2020.pdf (дата посещения: 28.03.20).

847. Ministero della Salute INDICAZIONI AD INTERIM PER LA PREVENZIONE E IL CONTROLLO DELL’INFEZIONE DA SARS-COV-2 IN STRUTTURE RESIDENZIALI SOCIOSANITARIE http://www.salute.gov.it/imgs/C_17_pagineAree_5373_9_file.pdf (дата посещения: 28.03.20).

848. Ministero della Salute Covid-19 – Sicurezza dei lavoratori https://bit.ly/3HIVUqW (дата посещения: 28.03.20).

849. WHO – https://apps.who.int/iris/bitstream/handle/10665/331215/WHO-2019-nCov-IPCPPE_use-2020.1-eng.pdf (дата посещения: 28.03.20).

850. Boechat JL, Chora I, Morais A, Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology – Current perspectives. Pulmonology. 2021 Sep-Oct;27 (5):423—437. doi: 10.1016/j. pulmoe.2021.03.008. Epub 2021 Apr 9. PMID: 33867315; PMCID: PMC8040543.

851. X. Lu, L. Zhang, H. Du, J. Zhang, Y. Li, J. Qu, et al. SARS-CoV-2 infection in children. N Engl J Med, 382 (2020), pp. 1663—1665, 10.1056/NEJMc2005073.

852. 9 S. Hoehl, H. Rabenau, A. Berger, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med, 382 (2020), pp. 1278—1280, 10.1056/NEJMc2001899.

853. G. Grasselli, A. Zangrillo, A. Zanella, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA, 323 (2020), pp. 1574—1581, 10.1001/jama.2020.5394. [published online ahead of print, 2020 April 6]

854. G. Lippi, C. Mattiuzzi, F. Sanchis-Gomar, B.M. Henry. Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China. J Med Virol (2020), 10.1002/jmv.25860.

855. N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al. A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 382 (2020), pp. 727—733, 10.1056/NEJMoa2001017.

856. Q.-X. Long, X.-J. Tang, Q.-L. Shi, Q. Li, H.-J. Deng, J. Yuan, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med, 26 (2020), pp. 1200—1204, 10.1038/s41591-020-0965-6.

857. C. Huang, Y. Wang, X. Li, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395 (2020), pp. 497—506, 10.1016/S0140—6736 (20) 30183—5. [published correction appears in Lancet. 2020 January 30]

858. F. Zhou, T. Yu, R. Du, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395 (2020), pp. 1054—1062, 10.1016/S0140—6736 (20) 30566—3 [published correction appears in Lancet. 2020 Mar 28;395 (10229):1038.

859. Y. Zhou, K. Lu, S. Pfefferle, et al. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. J Virol, 84 (2010), pp. 8753—8764, 10.1128/JVI.00554—10.

860. H. Zhang, G. Zhou, L. Zhi, et al. Association between mannose-binding lectin gene polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect Dis, 192 (2005), pp. 1355—1361, 10.1086/491479.

861. E. Andreakos, I. Zanoni, I.E. Galani. Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control. Curr Opin Immunol, 56 (2019), pp. 67—75, 10.1016/j.coi.2018.10.007.

862. A. Park, A. Iwasaki. Type I and Type III interferons – induction, signaling, evasion and application to combat Covid-19. Cell Host Microbe, 27 (2020), pp. 870—878, 10.1016/j.chom.2020.05.008.

863. X. Deng, Y. Chen, A.M. Mielech, et al. Structure-guided mutagenesis alters deubiquitinating activity and attenuates pathogenesis of a murine coronavirus. J Virol, 94 (2020), 10.1128/JVI.01734—19 e01734—19.

864. D. Blanco-Melo, B.E. Nilsson-Payant, W.-C. Liu, et al.Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 181 (2020), 10.1016/j. cell.2020.04.0261036—45.e9.

865. J. Hadjadj, N. Yatim, L. Barnabei, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science, 369 (2020), pp. 718—724, 10.1126/science. abc6027.

866. I.E. Galani, V. Triantafyllia, E.E. Eleminiadou, O. Koltsida, A. Stavropoulos, M. Manioudaki, et al. Interferon-λ mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity, 46 (2017), pp. 875—890, 10.1016/j.immuni.2017.04.025e6.

867. J. Klinkhammer, D. Schnepf, L. Ye, et al. IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. Elife, 7 (2018), p. e33354, 10.7554/eLife.33354.

868. L. Ye, D. Schnepf, P. Staeheli. Interferon-λ orchestrates innate and adaptive mucosal immune responses. Nat Rev Immunol, 19 (2019), pp. 614—625, 10.1038/s41577-019-0182-z.

869. J. Wang, Q. Li, Y. Yin, et al. Excessive neutrophils and Neutrophil Extracellular Traps in COVID-19. Front Immunol, 11 (2020), p. 2063, 10.3389/fimmu.2020.02063.

870. De Biasi, D. Lo Tartaro, M. Meschiari, et al. Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia. Eur J Immunol, 50 (2020), pp. 1283—1294, 10.1002/eji.202048838.

871. H. Li, L. Liu, D. Zhang, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet, 395 (2020), pp. 1517—1520, 10.1016/S0140—6736 (20) 30920-X.

872. P. Mehta, D.F. McAuley, M. Brown, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 395 (2020), pp. 1033—1034, 10.1016/S0140—6736 (20) 30628—0.

873. Y. Shoenfeld. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev, 19 (2020), p. 102538, 10.1016/j.autrev.2020.102538.

874. L. Wong, E. Loo, A. Kang, et al. Age-related differences in immunological responses to SARS-CoV-2. J Allergy Clin Immunol Pract, 8 (2020), pp. 3251—3258, 10.1016/j. jaip.2020.08.026

875. L.A. Henderson, S.W. Canna, G.S. Schulert, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol, 72 (2020), pp. 1059—1063, 10.1002/art.41285.

876. A. Alunno, F. Carubbi, J. Rodriguez-Carrio. Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin. RMD Open, 6 (2020), p. e001295, 10.1136/rmdopen-2020-001295.

877. A. Silvin, N. Chapuis, G. Dunsmore, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell, 182 (2020), pp. 1401—1418, 10.1016/j. cell.2020.08.002

878. Z. Varga, A.J. Flammer, P. Steiger, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet, 395 (2020), pp. 1417—1418, 10.1016/S0140—6736 (20) 30937—5.

879. C. Muus, M.D. Luecken, G. Eraslan, A. Waghray, G. Heimberg, L. Sikemma, et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv (2020), 10.1101/2020.04.19.049254.

880. T. Gao, M. Hu, X. Zhang, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv (2020), 10.1101/2020.03.29.20041962 preprint.

881. P. Conigliaro, P. Triggianese, C. Perricone, et al. COVID-19: disCOVering the role of complement system. Clin Exp Rheumatol, 38 (2020), pp. 587—591.

882. RCOG – Coronavirus Infection in Pregnancy – The Royal College of Obstetricians and Gynaecologists: https://www.rcog.org.uk/guidance/coronavirus-covid-19-pregnancy-and-women-s-health/coronavirus-covid-19-infection-in-pregnancy. Дата посещения 05.02.23.

883. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ (Clinical research ed.) 2020;370m3320.

884. Reale SC, Lumbreras-Marquez MI, King CH, et al. Patient characteristics associated with SARS-CoV-2 infection in parturients admitted for labour and delivery in Massachusetts during the spring 2020 surge: A prospective cohort study. Paediatric and perinatal epidemiology 2021;35 (1):24—33.

885. UK Health Security Agency: COVID-19: investigation and initial clinical management of possible cases. 2020.

886. Afshar Y, Gaw SL, Flaherman VJ, et al. Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People. Obstetrics and gynecology 2020;136 (6):1117—1125.

887. National Institute for Health and Care Excellence: [NG188] COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020.

888. Vousden N, Bunch K, Morris E, et al.: The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: A national cohort study using the UK Obstetric Surveillance System (UKOSS). PloS one 2021;16 (5):e0251123.

889. Polack FP, Thomas SJ, Kitchin N, et al.: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of medicine 2020;383 (27):2603—2615.

890. Voysey M, Clemens SAC, Madhi SA, et al.: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England) 2021;397 (10269):99—111.

891. Baden LR, El Sahly HM, Essink B, et al.: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine 021;384 (5):403—416.

892. Sadoff J, Gray G, Vandebosch AN, et al.: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. The New England journal of medicine 2021;384 (23):2187—2201.

893. Heath PT, Galiza EP, Baxter DN, et al.: Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. The New England journal of medicine 2021;385 (13):1172—1183.

894. Jara A, Undurraga EA, González C, et al.: Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. The New England journal of medicine 2021;385 (10):875—884.

895. UK Health Security Agency: COVID-19 vaccine weekly surveillance reports (weeks 39 to 35, 2021 to 2022). 2021.

896. UK Health Security Agency: COVID-19 vaccine surveillance report: 18 November 2021 (week 46). 2021.

897. Abu-Raddad LJ, Chemaitelly H, Butt AA: Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. The New England journal of medicine 2021;385 (2):187—189.

898. Lopez Bernal J, Andrews N, Gower C, et al.: Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. The New England journal of medicine 2021;385 (7):585—594.

899. UK Health Security Agency: Investigation of SARS-CoV-2 variants: technical briefings. 2021.

900. Flannery DD, Gouma S, Dhudasia MB, et al.: Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios. JAMA pediatrics 2021;175 (6):594—600.

901. Juncker HG, Romijn M, Loth VN, et al. Antibodies Against SARS-CoV-2 in Human Milk: Milk Conversion Rates in the Netherlands. Journal of human lactation: official journal of International Lactation Consultant Association 2021;37 (3):469—476.

902. RCPCH– COVID-19 – guidance for management of children admitted to hospital and for treatment of non-hospitalised children at risk of severe disease: https://www.rcpch.ac.uk/resources/covid-19-management-children-hospital-and-non-hospitalised. Дата посещения 05.02.23.

903. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. British Medical Journal. 2020. www.bmj.com/content/bmj/370/bmj.m3249.

904. Langford BJ et al., Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis, Clinical Microbiology and Infection, doi.org/10.1016/j.cmi.2020.07.016.

905. Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020 May;18 (3):167—169. doi: 10.2450/2020.0083—20. Epub 2020 Apr 8. PMID: 32281926; PMCID: PMC7250682.

906. ISTH – ISTH GUIDELINES ON COVID: https://www.isth.org/page/covidguidelines?&hhsearchterms=%22covid+and+guidelines%22. Дата посещения 05.02.23.

907. WHO – Drugs to prevent COVID-19: A WHO living guideline: https://app.magicapp.org/#/guideline/4959. Data di accesso 05.02.23.

908. WHO – COVID-19 rapid guideline: Managing COVID-19: https://app.magicapp.org/#/guideline/6782. Дата посещения 05—06.02.23.

909. NHS – Pulse oximetry to detect early deterioration of patients with COVID-19 in primary and community care settings: https://www.england.nhs.uk/coronavirus/publication/pulse-oximetry-to-detect-early-deterioration-of-patients-with-covid-19-in-primary-and-community-care-settings. Дата посещения 05—06.02.23.

910. NICE – COVID-19 rapid guideline: managing the long-term effects of COVID-19: https://www.nice.org.uk/guidance/ng188. Дата посещения 06.02.23.

911. NICE – Care of dying adults in the last days of life: https://www.nice.org.uk/guidance/ng31. Дата посещения 06.02.23.

912. NICE – End of life care for adults: service delivery: https://www.nice.org.uk/guidance/ng142. Дата посещения 06.02.23.

913. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: A review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020 May;101 (5):263—268. doi: 10.1016/j. diii.2020.03.014. Epub 2020 Apr 3. PMID: 32291197; PMCID: PMC7129663.

914. Pablos I, Machado Y, de Jesus HCR, et al. Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome. Cell Rep. 2021 Oct 26;37 (4):109892. doi: 10.1016/j. celrep.2021.109892. Epub 2021 Oct 9. PMID: 34672947; PMCID: PMC8501228.

915. Bertini P, Guarracino F, Falcone M, et al. ECMO in COVID-19 Patients: A Systematic Review and Meta-analysis. J Cardiothorac Vasc Anesth. 2022 Aug;36 (8 Pt A):2700—2706. doi: 10.1053/j. jvca.2021.11.006. Epub 2021 Nov 12. PMID: 34906383; PMCID: PMC8585556.

916. Ghosh S, Klein RS. Sex drives dimorphic immune responses to viral infections. J Immunol. 2017; 198:1782—90. https://doi.org/10.4049/jimmunol.1601166.

917. Srivastava A, Pandey RK, Singh PP, et al. Most frequent South Asian haplotypes of ACE2 share identity by descent with East Eurasian populations. PLoS One. 2020 Sep 16;15 (9):e0238255. doi: 10.1371/journal. pone.0238255. PMID: 32936832; PMCID: PMC7494073.

918. Shoily SS, Ahsan T, Fatema K, Sajib AA. Disparities in COVID-19 severities and casualties across ethnic groups around the globe and patterns of ACE2 and PIR variants. Infect Genet Evol. 2021 Aug;92:104888. doi: 10.1016/j.meegid.2021.104888. Epub 2021 Apr 30. PMID: 33933634; PMCID: PMC8084605.

919. Agenzia Italiana del Farmaco – Uso degli anticorpi monoclonali per COVID-19: https://www.aifa.gov.it/uso-degli-anticorpi-monoclonali#, Дата посещения 16.02.23.

920. GOLD POCKET GUIDE 2021. STRATEGIA GLOBALE PER LA DIAGNOSI, IL TRATTAMENTO E LA PREVENZIONE DELLA BPCO. https://goldcopd.it/wp-content/uploads/materiali/2021/GOLD_Pocket_2021.pdf, Дата посещения 19.02.23.

921. Falcetta P, Indovina FS, Coppelli A, et al. Inibitori di SGLT-2 e chetoacidosi euglicemica: conoscere per prevenire. Endocrinologo. 2019;20 (6):336—340. doi: 10.1007/s40619-019-00646-6.

922. De Cosmo S, Alessi E, Candido R et al (2020) Guida clinica alla prevenzione e gestione del COVID-19 nelle persone con diabete. A cura del Comitato Scientifico AMD. Available at https://aemmedi.it/wp-content/uploads/2020/03/Guida-clinica-prevenzione-COVID-19_25_03_20.pdf. Accessed on 02 April 2020.

923. Professional Practice Committee Standards of medical care in diabetes—2020. Diabetes Care. 2020;43 (Suppl 1):S3—S3.

924. Precisazioni AIFA su Malattia da coronavirus Covid-19 ed utilizzo di ACE-Inibitori e Sartani. Available at https://www.aifa.gov.it/-/precisazioni-aifa-su-malattia-da-coronavirus-covid-19-ed-utilizzo-di-ace-inibitori-e-sartani. Accessed on 08 April 2020.

925. Società Italiana dell’Ipertensione Arteriosa (2020) Comunicato SIIA Coronavirus e farmaci anti-ipertensivi. Available at https://siia.it/notizie-siia/farmaci-antiipertensivi-e-rischio-di-covid-19-il-comunicato-della-siia. Accessed on 12 April 2020.

926. Apicella M, Campopiano MC, Mantuano M, et al. Guida pratica alla prevenzione e gestione dell’infezione da COVID-19 nelle persone con diabete. L’Endocrinologo. 2020;21 (4):241—5. Italian. doi: 10.1007/s40619-020-00767-3. Epub 2020 Oct 23. PMCID: PMC7582423.

927. Diabete.com. Covid-19 e diabete: raccomandazioni pratiche per la gestione del diabete in pazienti con l’infezione: https://www.diabete.com/diabete-covid19-raccomandazioni-pratiche-la-gestione-del-diabete-pazienti-infezione. Дата посещения 19.02.23.

928. Nørgaard C. Telemedicine consultations and diabetes technology during COVID-19. J Diabetes Sci and Technol. 2020; https://doi.org/10.1177/1932296820929378.

929. Tornese G., Ceconi V., Monasta L. et al. Glycemic control in type 1 diabetes mellitus during covid-19 quarantine and the role of in-home physical activity. Diab Technol Therap. 2020; 22 https://doi.org/10.1089/dia.2020.0169.

930. d’Annunzio G, Maffeis C, Cherubini V, et al. Caring for children and adolescents with type 1 diabetes mellitus: Italian Society for Pediatric Endocrinology and Diabetology (ISPED) statements during COVID-19 pandemia. Diabetes Res Clin Pract. 2020 Oct;168:108372. doi: 10.1016/j. diabres.2020.108372. Epub 2020 Aug 20. PMID: 32827594; PMCID: PMC7438223.

931. Korytkowski M, Antinori-Lent K, Drincic A, et al. A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic. J Clin Endocrinol Metab. 2020 Sep 1;105 (9):dgaa342. doi: 10.1210/clinem/dgaa342. PMID: 32498085; PMCID: PMC7313952.

932. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369 (14):1317—1326.

933. Toh S, Hampp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016;164 (11):705—714.

934. Umpierrez GE, Korytkowski M. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care. 2013;36 (7):2112—2117.

935. Bardia A, Wai M, Fontes ML. Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications. Curr Opin Anaesthesiol. 2019;32 (1):80—85.

936. Seggelke SA, Gibbs J, Draznin B. Pilot study of using neutral protamine Hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes. J Hosp Med. 2011;6 (3):175—176.

937. Priyambada L, Wolfsdorf JI, Brink SJ, et al. ISPAD Clinical Practice Consensus Guideline: Diabetic ketoacidosis in the time of COVID-19 and resource-limited settings-role of subcutaneous insulin. Pediatr Diabetes. 2020 Dec;21 (8):1394—1402. doi: 10.1111/pedi.13118. Epub 2020 Oct 12. PMID: 32935435.

938. Pathan F, Selim S, Fariduddin M, et al. BES Diabetes and COVID Task Force. Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19. Diabetes Metab Syndr Obes. 2021 May 18;14:2217—2228. doi: 10.2147/DMSO. S293688. PMID: 34040407; PMCID: PMC8140905.

939. Czupryniak L, Dicker D, Lehmann R, Prázný M, Schernthaner G. The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence? Cardiovasc Diabetol. 2021 Oct 1;20 (1):198. doi: 10.1186/s12933-021-01389-1. PMID: 34598700; PMCID: PMC8485772.

940. Dardano A, Del Prato S. Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19? Lancet Healthy Longev. 2021;2:e6—7.

941. Giugliano D, et al. Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized pragmatic trial. Diabetes Care. 2021;44:1353—60.

942. Catargi B, Cheisson G, Tauveron I, Jacqueminet S, Benhamou D. Diabetes care during the acute phase of infection in ICU patients with specific attention to COVID-19 outbreak. Anaesth Crit Care Pain Med. 2020 Jun;39 (3):375—379. doi: 10.1016/j.accpm.2020.06.004. Epub 2020 Jun 17. PMID: 32620420; PMCID: PMC7832562.

943. Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, et al. Scientific Reviewer Committee. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost. 2020 Dec;120 (12):1597—1628. doi: 10.1055/s-0040-1715798. Epub 2020 Sep 13. PMID: 32920811; PMCID: PMC7869052.

944. British Society of Gastroenterology – Guidance for management of inflammatory bowel disease during the COVID-19 pandemic: https://www.bsg.org.uk/clinical-resource/guidance-for-management-of-inflammatory-bowel-disease-during-the-covid-19-pandemic. Дата посещения 20.02.23.

945. Huf WE, Valipour A. Vaccination against SARS-CoV-2 in adults with a diagnosis of cancer: a short review. Memo. 2023 Jan 5:1—6. doi: 10.1007/s12254-022-00858-x. Epub ahead of print. PMID: 36628356; PMCID: PMC9815670.

946. NCCN. NCCN: cancer and COVID-10 vaccination. 2022. Version 7.0 09/22/20222022.

947. RKI. Epidemiol Bull. 2022;40:14—18.

948. NIG. COVID-19-Impfungen: Anwendungsempfehlungen des Nationalen Impfgremiums. https://bit.ly/3KxqN4g. Accessed 10 Aug 2022, Version 10.32022.

949. NIG. COVID-19-Impfungen: Herbst 2022. 2022. https://bit.ly/3ZEN9oW. Accessed 8 Oct 2022.